Ceredex Value Advisors LLC Invests $17.52 Million in Humana Inc. $HUM

Ceredex Value Advisors LLC acquired a new stake in Humana Inc. (NYSE:HUM) in the second quarter, HoldingsChannel.com reports. The firm acquired 71,650 shares of the insurance provider’s stock, valued at approximately $17,517,000.

Other large investors have also recently added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC boosted its stake in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after buying an additional 46 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new position in shares of Humana during the 2nd quarter worth about $32,000. Zions Bancorporation National Association UT acquired a new stake in shares of Humana in the first quarter worth approximately $37,000. AlphaCore Capital LLC purchased a new stake in Humana in the second quarter valued at approximately $39,000. Finally, CVA Family Office LLC grew its holdings in Humana by 63.4% in the second quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock valued at $54,000 after purchasing an additional 85 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group decreased their price target on shares of Humana from $235.00 to $215.00 and set a “sell” rating on the stock in a report on Monday. Mizuho increased their target price on Humana from $300.00 to $345.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. Piper Sandler lowered their price target on Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a research report on Thursday, July 31st. Barclays dropped their price target on Humana from $245.00 to $234.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a research note on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $295.94.

Humana Trading Up 3.3%

Shares of HUM opened at $245.73 on Friday. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $315.35. The stock’s 50-day moving average is $263.32 and its two-hundred day moving average is $256.70. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The stock has a market cap of $29.55 billion, a PE ratio of 18.86, a P/E/G ratio of 1.71 and a beta of 0.42.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating the consensus estimate of $2.95 by $0.29. The business had revenue of $32.65 billion for the quarter, compared to the consensus estimate of $31.99 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company’s revenue was up 11.1% on a year-over-year basis. During the same period last year, the business posted $4.16 EPS. Equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.4%. Humana’s dividend payout ratio (DPR) is currently 33.18%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.